Team GP2

Exploring Genetic Differences in Parkinson’s Disease by Ancestry

08/04/2026 — A landmark international study has found that the genetic drivers of Parkinson’s disease can vary dramatically between populations, underscoring the need to include people of various ancestries in genetic research and clinical trials.

Turning on the data tap at GP2

07/22/2026 — A new paper in the journal JAMA Neurology presents a progress report from the Global Parkinson Genetics Program, or “GP2.” That’s a world-wide collaboration to study the genetics not only Parkinson’s disease, but also dementia with Lewy bodies, multiple system atrophy, corticobasal degeneration — and PSP.

The Components of GP2’s 12th Data Release

06/30/2026 — In July 2026, GP2 announced the 12th data release on the Terra and the Verily® Workbench platforms in collaboration with AMP® PDRD. This release includes 21,156 additional genotyped participants and 25,046 additional whole genome sequencing (WGS) participants.

CMUL to strengthen capacity in molecular diagnostics

06/16/2026 — Members of the College of Medicine, University of Lagos (CMUL), have restated commitment to strengthening capacity development in molecular diagnostics for improved healthcare delivery. They spoke at a workshop on transforming clinical diagnostics with Polymerase Chain Reaction (PCR) Technology; From Microbiome Analysis to HPV Genotyping held at the Idi-Araba campus Lagos recently. The participants embarked on a facility tour of the University of Lagos Centre for Neurological Sciences Research and Training (CENSRT) newly commissioned Global Parkinson’s Genetics Program (GP2) – CMUL Molecular Laboratory.

Pathology and Genetics in a Global Cohort of Parkinsonian Disorders

— How are genetic variants and neuropathology associated with clinical features and diagnostic accuracy in movement disorders? In this multiancestry brain bank cross-sectional study including over 3000 individuals, clinical misdiagnosis was common; dementia with parkinsonism was more strongly associated with Lewy body (LB) pathology than Parkinson disease without dementia, and Alzheimer disease copathology was frequent. Genetic variation was associated with pathological differences; GBA1 carriers had greater LB burden, whereas carriers of the LRRK2 pathogenic variant had a lower LB burden and longer survival.